Creating vaccines to protect against infectious diseases and bioterrorism
Official title: Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
Funded at Anivive Lifesciences, INC · NIH-11196803 · Data updated 2026-11-12
This study is working on creating new vaccines to help protect people from infectious diseases, especially during outbreaks or emergencies, and it’s testing these vaccines in animals to make sure they are safe and effective before they can be used in humans.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Anivive Lifesciences, INC NIH-funded |
| Lab location | 1 site (Long Beach, United States) |
| Project start | June 7, 2024 |
| Project end | June 1, 2026 |
| Funding year | 2024 |
| Award (this year) | $4,889,710 |
| NIH project number | 75N93024C00009-0-9999-1 |
| Project ID | NIH-11196803 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research would include individuals at risk of exposure to emerging infectious diseases or those living in areas prone to outbreaks.
✕Less likely to help
Patients who are not at risk for infectious diseases or who have existing immunity to the targeted pathogens may not receive benefit from this research.
What this research studies
This research focuses on developing vaccine candidates that can be used in response to outbreaks of infectious diseases, including those that may arise from bioterrorism. The approach involves formulating and manufacturing vaccine components, conducting stability tests, and evaluating their effectiveness and safety through nonclinical studies in animal models. If successful, this research aims to advance these vaccine candidates towards clinical trials, ensuring they are safe and effective for human use.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines that protect against serious infectious diseases and bioterrorism threats.
How similar studies have gone: Other research has shown success in developing vaccines for infectious diseases, indicating that this approach has potential for significant advancements.
Where this research is happening
-
Anivive Lifesciences, INC
Long Beach, United States Active
Researchers
- Principal investigator: Bruyette, David — Anivive Lifesciences, INC
- Study coordinator: Bruyette, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.